Biohaven’s ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months – Biohaven Pharma Hldgs (NYSE:BHVN)
[ad_1] Biohaven Pharmaceutical Holding Company Ltd BHVN announced results from a focused analysis of verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). Verdiperstat did not statistically…